Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

ISA Pharmaceuticals' CSO Prof. Cornelis Melief to Present at CRI-CIMT-EATI-AACR Meeting in New York City

ISA Pharmaceuticals
Posted on: 21 Sep 16

- Prof. Melief co-chairs Plenary Session 1: Antigens and Vaccines


Leiden, The Netherlands, September 21, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that Prof. Cornelis Melief, M.D., and Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO, will jointly chair "Plenary Session 1: Antigens and Vaccines" on September 25, 2016, 8:50 am - 12:00 pm EST at the upcoming CRI-CIMT-EATI-AACR Meeting in New York City.


During the session, Melief will give a presentation titled "Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination", outlining recent progress in the field.




About ISA Pharmaceuticals


ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology, which have the potential to generate safe and effective immunologic responses with a known mechanism of action. Synthetic long peptides are broadly applicable to multiple targets and ideally suited for monotherapy, as essential components in combination with conventional cancer treatments, and with novel immunomodulators such as Nivolumab. SLP® immunotherapies are designed to fully harness and direct the body's own defenses towards fighting the disease. In addition, ISA has begun to develop personalized SLP® immunotherapies targeting tumor-specific, mutation-derived neo-antigens. These SLP®s are based on the analysis of specific DNA mutations in a tumor sample, and designed and synthesized for each individual patient.


ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Moreover, a clinical Phase II combination trial with ISA101 and Nivolumab is being conducted at the MD Anderson Cancer Center in the US. Clinical proof-of-concept of ISA101 has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.


The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit


SLP® and AMPLIVANT® are registered trademarks in Europe.



Contact & Media Inquiries:


Dr. Ludger Wess                Ines-Regina Buth

Managing Partner              Managing Partner

Tel. +49 40 88 16 59 64    Tel. +49 30 23 63 27 68



For more information:

Editor's Details

Ines-Regina Buth

Last updated on: 21/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.